Bayer Adds Legal Help To Resolve Liabilities -- WSJ
June 27 2019 - 3:02AM
Dow Jones News
By Ruth Bender and Ben Dummett
This article is being republished as part of our daily
reproduction of WSJ.com articles that also appeared in the U.S.
print edition of The Wall Street Journal (June 27, 2019).
BERLIN -- Bayer AG on Wednesday bowed to pressure from
investors, saying it would seek outside help and review its
approach in the legal battle with thousands of cancer patients who
blame the herbicide Roundup for their illness.
The chemicals and pharmaceutical giant said it would create a
special committee of eight supervisory board members to monitor
Roundup lawsuits and consult with management on legal
strategies.
It also named U.S. lawyer John H. Beisner, an expert on mass
tort and product litigation at Skadden, Arps, Slate, Meagher &
Flom LLP, to advise the board on all Roundup legal matters,
including trial tactics and mediation.
Bayer cited Mr. Beisner's experience in negotiating high-profile
settlements and said it looked forward to "constructively engaging
in the mediation process." A U.S. judge has provisionally appointed
Kenneth Feinberg to serve as mediator in the consolidation of
hundreds of Roundup cases filed in federal court. Mr. Feinberg has
served as mediator in high-profile cases, including the Deepwater
Horizon oil spill in the Gulf of Mexico in 2010.
Bayer has faced mounting pressure from shareholders to show it
is taking concrete action to resolve litigation over its Roundup
weedkillers -- a legal battle involving more than 13,000 plaintiffs
that has wiped out some 40% of the company's market value over the
past year. Shareholders have been venting their anger at management
for entangling the company in a damaging legal fight by buying
Roundup creator Monsanto Co. last year.
U.S. hedge fund Elliott Management Corp., which owns some EUR1.1
billion ($1.25 billion) worth of Bayer shares, or about 2% of the
company, backed Bayer's latest steps. It said the new committee
would provide "a new level of oversight and a fresh perspective to
a litigation strategy in need of radical overhaul and help guide
the company towards a rational, fair and swift settlement."
Since taking over Monsanto, Bayer has lost the first three
Roundup jury trials in California, with the last award topping $2
billion. Analysts have warned the legal fight could take years to
resolve and potentially cost the company billions.
Bayer, which argues that Roundup and its active ingredient,
glyphosate, are safe, is appealing the verdicts.
The German company has been trying to win back investors' trust
after the mounting legal woes engendered enormous frustration with
management.
"The supervisory board recognizes the negative effect the
litigation uncertainty has had on the stock price and stakeholder
perception, and is determined to help the company decisively but
prudently advance the matter," Bayer said Wednesday.
The company said it was also considering adding new experts in
food and agriculture to the board.
Chief Executive Werner Baumann, the architect of the Monsanto
deal, has drawn most of the criticism. At Bayer's general meeting
in late April, a majority of shareholders for the first time in
German postwar history voted against the chief executive of a
DAX-listed company. While the vote isn't binding, it was a clear
warning to Mr. Baumann and his team that management had mishandled
the Roundup crisis and needed to change its approach.
Some shareholders accused Bayer managers of underestimating the
legal and reputational risks of acquiring Monsanto. Bayer said it
acted conscientiously and commissioned a law firm to back its
defense that its due diligence was thorough.
Furious about the loss in value and fearing further damage to
Bayer, some institutional shareholders, including Germany's Deka
Investment, demanded that Bayer reshape its supervisory board to
better deal with the current legal challenge and the group's
increased presence in crop science. Some also said they wanted the
company to bring in an expert to deal with the Roundup
litigation.
Elliott said that while resolving the legal challenge is an
immediate priority, "Bayer could do more to maximize long-term
value for all its stakeholders." Some analysts have said Bayer's
fragile position could lead to activist investors pushing for a
more drastic change at the company, such as splitting the drugs
business from its crop-science operations.
Write to Ruth Bender at Ruth.Bender@wsj.com and Ben Dummett at
ben.dummett@wsj.com
(END) Dow Jones Newswires
June 27, 2019 02:47 ET (06:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Apr 2024 to May 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From May 2023 to May 2024